Your browser doesn't support javascript.
loading
Discovery of a potent protein kinase D inhibitor: insights in the binding mode of pyrazolo[3,4-d]pyrimidine analogues.
Verschueren, Klaas; Cobbaut, Mathias; Demaerel, Joachim; Saadah, Lina; Voet, Arnout R D; Van Lint, Johan; De Borggraeve, Wim M.
Affiliation
  • Verschueren K; Department of Chemistry , Molecular Design and Synthesis , KU Leuven , Celestijnenlaan 200F , 3001 Leuven , Belgium . Email: wim.deborggraeve@kuleuven.be.
  • Cobbaut M; Department of Cellular and Molecular Medicine , Laboratory of Protein Phosphorylation and Proteomics , KU Leuven , Herestraat 49 box 901 , 3000 Leuven , Belgium.
  • Demaerel J; Department of Chemistry , Molecular Design and Synthesis , KU Leuven , Celestijnenlaan 200F , 3001 Leuven , Belgium . Email: wim.deborggraeve@kuleuven.be.
  • Saadah L; Department of Cellular and Molecular Medicine , Laboratory of Protein Phosphorylation and Proteomics , KU Leuven , Herestraat 49 box 901 , 3000 Leuven , Belgium.
  • Voet ARD; Department of Chemistry , Laboratory of Biomolecular Modeling and Design , KU Leuven , Celestijnenlaan 200G , 3001 Leuven , Belgium.
  • Van Lint J; Department of Cellular and Molecular Medicine , Laboratory of Protein Phosphorylation and Proteomics , KU Leuven , Herestraat 49 box 901 , 3000 Leuven , Belgium.
  • De Borggraeve WM; Department of Chemistry , Molecular Design and Synthesis , KU Leuven , Celestijnenlaan 200F , 3001 Leuven , Belgium . Email: wim.deborggraeve@kuleuven.be.
Medchemcomm ; 8(3): 640-646, 2017 Mar 01.
Article in En | MEDLINE | ID: mdl-28890776
ABSTRACT
In this study, we set out to rationally optimize PKD inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. The lead compound for this study was 1-NM-PP1, which was previously found by us and others to inhibit PKD. In our screening we identified one compound (3-IN-PP1) displaying a 10-fold increase in potency over 1-NM-PP1, opening new possibilities for specific protein kinase inhibitors for kinases that show sensitivity towards pyrazolo[3,4-d]pyrimidine derived compounds. Interestingly the observed SAR was not in complete agreement with the commonly observed binding mode where the pyrazolo[3,4-d]pyrimidine compounds are bound in a similar fashion as PKD's natural ligand ATP. Therefore we suggest an alternate binding mode where the compounds are flipped 180 degrees. This possible alternate binding mode for pyrazolo[3,4-d]pyrimidine based compounds could pave the way for a new class of specific protein kinase inhibitors for kinases sensitive towards pyrazolo[3,4-d]pyrmidines.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Medchemcomm Year: 2017 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Medchemcomm Year: 2017 Document type: Article